Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Hypoglycemia has been associated with an increased risk of cardiovascular (CV) events and all-cause mortality. This study assessed whether, in a nationally representative population, there is an association between hypoglycemia, the risk of CV events, and all-cause mortality among insulin-treated people with type 1 diabetes or type 2 diabetes. RESEARCH DESIGN AND METHODS: This retrospective cohort study used data from the Clinical Practice Research Datalink database and included all insulin-treated patients (≥30 years of age) with a diagnosis of diabetes. RESULTS: In patients who experienced hypoglycemia, hazard ratios (HRs) for CV events in people with type 1 diabetes were 1.51 (95% CI 0.83, 2.75; P = ns) and 1.61 (1.17, 2.22), respectively, for those with and without a history of CV disease (CVD) before the index date. In people with type 2 diabetes, the HRs for patients with and without a history of CVD were 1.60 (1.21, 2.12) and 1.49 (1.23, 1.82), respectively. For all-cause mortality, HRs in people with type 1 diabetes were 1.98 (1.25, 3.17), and 2.03 (1.66, 2.47), respectively, for those with and without a history of CVD. Among people with type 2 diabetes, HRs were 1.74 (1.39, 2.18) and 2.48 (2.21, 2.79), respectively, for those with and without a history of CVD. The median time (interquartile range) from first hypoglycemia event to first CV event was 1.5 years (0.5, 3.5 years) and 1.5 years (0.5, 3.0 years), respectively, for people with type 1 and type 2 diabetes. CONCLUSIONS: Hypoglycemia is associated with an increased risk of CV events and all-cause mortality in insulin-treated patients with diabetes. The relationship between hypoglycemia and CV outcomes and mortality exists over a long period.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CVD mortality accounts for 30-44% of all deaths in patients with T1DM.[780][781][782][783][784]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [782]
In the citing paper
“People with T1DM face a three-fold increase in mortality compared with the general population”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [782]
In the citing paper
“which translates into an 11-year reduction in life expectancy”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [782]
In the citing paper
“multiple studies have shown a strong relationship between hypoglycemia (severe or not severe) and cardiovascular events and mortality”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [200]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 1×
“Since the ACCORD and VADT results were published, attempts have been made to assess whether a relationship exists between hypoglycemia and CV risk or mortality, but only recently has a consensus begun to emerge suggesting that there is a link between the two (6,8,9).”
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Severe hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471
Cited by
Items 101–200 of 355
Jangam, S. R., Dunn, T. C., Xu, Y., Hayter, G., & Ajjan, R. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000611 · Cited by 30
Hypoglycaemia in type 1 diabetes mellitus: risks and practical prevention strategies
Kaur, J., & Seaquist, E. R. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00762-8 · Cited by 38
Takahashi, Y., Nomoto, H., Yokoyama, H., Takano, Y., Nagai, S., Tsuzuki, A., Cho, K. Y., Miya, A., Kameda, H., Takeuchi, J., et al. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14998 · Cited by 29
“mic episodes are related to increases of cardiovascular events and reductions of quality of life.(4,5) Currently, various antihyperglycaemic drugs are available in clinical practice, but the ideal drugs would have the following conditions: strong glucose-lowering effect without causing body weight gain, low risk of hy…”
BackgroundRenal Tubular Handling of Glucose and Fructose in Health and Disease
Vallon, V., & Nakagawa, T. (2021) · Comprehensive physiology · doi:10.1002/cphy.c210030 · Cited by 54
Glucagon prescribing and costs among U.S. Adults with diabetes, 2011–2021
Herges, J. R., Galindo, R. J., Neumiller, J. J., Heien, H. C., Umpierrez, G. E., & McCoy, R. G. (2023) · Diabetes Care · doi:10.2337/dc22-1564 · Cited by 28
Tsuji, S., Ishikawa, T., Morii, Y., Zhang, H., Suzuki, T., Tanikawa, T., Nakaya, J., & Ogasawara, K. (2020) · Journal of Medical Internet Research · doi:10.2196/16053 · Cited by 29
“Proactive treatments to lower blood glucose levels, however, are leading to increases in the occurrence of cardiovascular disease and coma as side effects of hypoglycemia [5,6].”
BackgroundMesa, A., Giménez, M., Pueyo, I., Perea, V., Viñals, C., Blanco, J., Vinagre, I., Serés‐Noriega, T., Boswell, L., Esmatjes, E., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109938 · Cited by 30
Wang, Y., Lu, J., Ni, J., Wang, M., Shen, Y., Lu, W., Zhu, W., Bao, Y., Rodbard, D., Vigersky, R. A., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15068 · Cited by 33
Toresson Grip, E., Svensson, A.-M., Miftaraj, M., Eliasson, B., Franzén, S., Gudbjörnsdottir, S., & Steen Carlsson, K. (2019) · Diabetes Care · doi:10.2337/dc18-1850 · Cited by 25
“In practice, where individuals with type 1 diabetes face challenges of the disease in daily management, the two modes of insulin administration could differ in effectiveness, ease of use, and association with adverse events and, therefore, be associated with differences in patient outcomes (1,3,4).”
BackgroundWake, A. D. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i3.161 · Cited by 36
Kalyani, R. R., Allende-Vigo, M. Z., Antinori-Lent, K. J., Close, K. L., Das, S. R., Deroze, P., Edelman, S. V., El Sayed, N. A., Kerr, D., Neumiller, J. J., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad745 · Cited by 25
Roumie, C. L., Min, J. Y., Greevy, R. A., Grijalva, C. G., Hung, A. M., Liu, X., Elasy, T. A., & Griffin, M. R. (2016) · Canadian Medical Association Journal · doi:10.1503/cmaj.150904 · Cited by 28
Chamarthi, B., & Cincotta, A. H. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1315290 · Cited by 25
Adjah, E. S. O., Montvida, O., Agbeve, J., & Paul, S. K. (2017) · The Open Bioinformatics Journal · doi:10.2174/1875036201710010016 · Cited by 25
“Miscoding between type 1 and type 2 diabetes in the primary care database is not uncommon [40, 41].”
BackgroundSelf-citationRenoprotective Effects of SGLT2 Inhibitors
Vallon, V. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.005 · Cited by 33
Exercise and Postprandial Glycemic Control in Type 2 Diabetes
Kearney, M. L., & Thyfault, J. P. (2016) · Current Diabetes Reviews · doi:10.2174/1573399811666150615112441 · Cited by 29
Soliman, E. Z., Backlund, J. C., Bebu, I., Orchard, T. J., Zinman, B., & Lachin, J. M. (2017) · Diabetes Care · doi:10.2337/dc16-2050 · Cited by 24
Huang, C., Wang, W., Sung, S., Chen, C., Lip, G. Y. H., Cheng, H., & Chiang, C. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13342 · Cited by 24
“Another cohort study has also confirmed this positive relationship.(19) Given that new T2D drugs are less prone to hypoglycaemia, their benefit-harm profiles on cardiovascular outcomes might be considerably different from those of conventional antihyperglycaemic agents.”
ResultGuo, J. S., Erqou, S. A., Miller, R. G., Edmundowicz, D., Orchard, T. J., & Costacou, T. (2018) · Diabetologia · doi:10.1007/s00125-018-4764-2 · Cited by 25
Mattishent, K., Richardson, K., Dhatariya, K., Savva, G. M., Fox, C., & Loke, Y. K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13769 · Cited by 25
Anyanwagu, U., Mamza, J., Donnelly, R., & IDRIS, I. R. (2019) · Age and Ageing · doi:10.1093/ageing/afy178 · Cited by 28
Liu, L., Liu, J., Xu, L., Ke, W., Wan, X., Li, H., He, X., Wang, L., Cao, X., Xiao, H., et al. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12782 · Cited by 28
Philis‐Tsimikas, A., STRATTON, I. M., Troelsen, L. N., Bak, B. A., & Leiter, L. A. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819841585 · Cited by 22
Zaccardi, F., Davies, M. J., & Khunti, K. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13929 · Cited by 23
Self-citationBoscari, F., Morieri, M. L., Amato, A. M. L., Vallone, V., Uliana, A., Baritussio, A., Vitturi, N., Cipponeri, E., Cavallin, F., Avogaro, A., et al. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.07.006 · Cited by 26
Severe Hypoglycemia Attributable to Intensive Glucose-Lowering Therapy Among US Adults With Diabetes
Mahoney, G. K., Henk, H. J., & McCoy, R. G. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.02.028 · Cited by 26
McLarnon, S. R., Patel, B., Irsik, D. L., Sun, J., Ocasio, H., Crislip, G. R., Jin, C., Chen, J., Baban, B., Polichnowski, A. J., et al. (2018) · Clinical Science · doi:10.1042/cs20171630 · Cited by 22
Li, G., Zhong, S., Wang, X., & Zhuge, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1222409 · Cited by 26
Practical Approaches to Diagnosing, Treating and Preventing Hypoglycemia in Diabetes
Kreider, K. E., Pereira, K. C., & Padilla, B. I. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0325-9 · Cited by 22
“This risk is primarily cardiovascular related and is seen most often in patients with diabetes who are treated with insulin [13].”
BackgroundEvans, M., Mehta, R., Gundgaard, J., & Chubb, B. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0478-1 · Cited by 22
Ducluzeau, P., Fauchier, G., Herbert, J., Semaan, C., Halimi, J., Angoulvant, D., & Fauchier, L. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101429 · Cited by 20
Roe, E. D., Chamarthi, B., & Raskin, P. (2015) · Journal of Diabetes Research · doi:10.1155/2015/834903 · Cited by 22
“While insulin is an effective treatment for hyperglycemia, it carries the potential for undesirable side effects such as hypoglycemia and weight gain, which in turn can lead to a worsening ability to manage diabetes [3–8].”
BackgroundInsulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults*
Strandberg, A. Y., Khanfir, H., Mäkimattila, S., Saukkonen, T. T., Strandberg, T. E., & Hoti, F. J. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1278302 · Cited by 19
“Serious hypoglycemia is associated with elevated mortality and risk of cardiovascular events, hospitalization, and subsequent costs (1,2).”
BackgroundWang, M., Huang, Y., Lai, J., Lee, C., Wang, P.-C., Pan, H.-Y., Lin, C., Liou, J., & Hsu, Y. (2022) · Diabetes Care · doi:10.2337/dc21-1779 · Cited by 21
Challenges in pancreas transplantation
Sharples, E. J., Mittal, S., & Friend, P. J. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0865-x · Cited by 21
“sufficient glycaemic control to avoid the development of diabetic complications is difficult to achieve, and many patients risk hypoglycaemia, and the development of disabling and life-threatening complications [14, 15].”
McCoy, R. G., Herrin, J., Galindo, R. J., Sindhu Swarna, K., Umpierrez, G. E., Hill Golden, S., & O'Connor, P. J. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110263 · Cited by 20
Riveline, J., Vergès, B. L., Detournay, B., Picard, S., Benhamou, P., Bismuth, É., Bordier, L., Jeandidier, N., Joubert, M., Roussel, R., et al. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101306 · Cited by 20
Allo Beta Cell transplantation: specific features, unanswered questions, and immunological challenge
Caldara, R., Tomajer, V., Monti, P., Sordi, V., Citro, A., Chimienti, R., Gremizzi, C., Catarinella, D., Tentori, S., Paloschi, V., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1323439 · Cited by 20
“Hypoglycemia rates remain signi fi cant, impacting patients ’ cognitive function (34 – 38), cardiovascular health (39 – 42), and quality (43, 44) and quantity of life.”
BackgroundFelix dies natalis, insulin… ceterum autem censeo “beta is better”
Piemonti, L. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01737-3 · Cited by 19
Nimri, R., Yakoob, H., Schoenberg, B. E., & Dassau, E. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.2504 · Cited by 20
Jiang, D. H., Herrin, J., Van Houten, H. K., & McCoy, R. G. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.50602 · Cited by 17
Cardiovascular Magnetic Resonance as Pathophysiologic Tool in Diabetes Mellitus
Mavrogeni, S. I., Bacopoulou, F., Markousis‐Mavrogenis, G., Giannakopoulou, A., Kariki, O. K., Vartela, V., Kolovou, G. D., Charmandari, E., & Chrousos, G. P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.672302 · Cited by 20
“Three-fold higher mortality has been identified in patients with type 1 diabetes mellitus (T1DM) compared to controls, due to premature atherosclerosis in both men and women (5).”
BackgroundStem cell therapy for insulin-dependent diabetes: Are we still on the road?
Yang, L., Hu, Z.-M., Jiang, F.-X., & Wang, W. (2022) · World Journal of Stem Cells · doi:10.4252/wjsc.v14.i7.503 · Cited by 14
Pathophysiology and management of hypoglycemia in diabetes
RANGEL, E. S., Deajon-Jackson, J. D., & Hwang, J. J. (2022) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14904 · Cited by 21
Montvida, O., Arandjelović, O., Reiner, E., & Paul, S. K. (2017) · The Open Bioinformatics Journal · doi:10.2174/1875036201709010001 · Cited by 16
Self-citationDiabetes and cardiovascular disease: from new mechanisms to new therapies
Gajos, G. (2018) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.4227 · Cited by 24
Mühlbacher, A. C., Sadler, A., & Juhnke, C. (2021) · The European Journal of Health Economics · doi:10.1007/s10198-021-01264-6 · Cited by 19
“5 years after the first onset of hypoglycemia [49].”
BackgroundLee, Y., Han, K., Kim, B., Choi, M. S., Park, J., Kim, M., Jin, S., Hur, K. Y., Kim, G., & Kim, J. H. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13539 · Cited by 20
Hypoglycaemia, thrombosis and vascular events in diabetes
King, R., & Ajjan, R. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2016.1215916 · Cited by 17
“A number of studies have since demonstrated close associations between hypoglycemia, increased rate of cardiovascular disease, and mortality in T2DM patients [7–13] and possibly T1DM [10,14], further emphasizing the limitations of HbA1c as the sole measure of glycemic control.”
BackgroundInfluentialPilla, S. J., Kraschnewski, J. L., Lehman, E. B., Kong, L., Francis, E., Poger, J. M., Bryce, C. L., Maruthur, N. M., & Yeh, H.-C. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002153 · Cited by 16
Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes
Katsiki, N., Kotsa, K., Stoian, A. P., & Mikhailidis, D. P. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200909142658 · Cited by 16
Martínez-Ortega, A., Muñoz-Gómez, C., Gros-Herguido, N., Remón-Ruíz, P., Acosta-Delgado, D., Losada-Viñau, F., Pumar-López, A., Mangas-Cruz, M., González-Navarro, I., López-Gallardo, G., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11041039 · Cited by 16
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.
Papagianni, M., & Τζιόμαλος, Κ. (2015) · Europe PMC (PubMed Central) · Cited by 21
Choi, S.-Y., & Ko, S. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.327 · Cited by 18
Cardiovascular risk management in type 1 diabetes
Teoh, I. H., Elisaus, P., & Schofield, J. D. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01400-9 · Cited by 15
Zaccardi, F., Webb, D. R., Davies, M. J., Dhalwani, N. N., Housley, G., Shaw, D., Hatton, J. W., & Khunti, K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12941 · Cited by 15
Self-citationMcEwan, P. C., Bennett, H., Bolin, K., Evans, M., & Bergenheim, K. (2018) · Diabetic Medicine · doi:10.1111/dme.13590 · Cited by 18
Moser, O., Rafferty, J., Eckstein, M. L., Aziz, F., Bain, S. C., Bergenstal, R. M., Sourij, H., & Thomas, R. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15102 · Cited by 17
Li, X., Kan, Y., Liu, H.-Y., Pang, J., He, Y., Liu, L., Zou, Y., Zhang, N., & Zhang, Y. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02102-2 · Cited by 17
Luk, A. O. Y., Ho, T. S. T., Lau, E. S. H., Ko, G. T. C., Ozaki, R., Tsang, C.-C., Kong, A. P. S., Ronald, C. W., So, W., Chow, F. C. C., et al. (2016) · Medicine · doi:10.1097/md.0000000000005183 · Cited by 18
Mohr, G. H., Søndergaard, K. B., Pallisgaard, J. L., Møller, S., Wissenberg, M., Karlsson, L., Hansen, S. M., Kragholm, K. H., Køber, L., Lippert, F. K., et al. (2020) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872618823349 · Cited by 15
Schwartz, S. S., & Herman, M. E. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1043182 · Cited by 14
“Indeed, the authors believe a goal of diabetes management includes achieving glycemic control while avoiding hypoglycemia and weight gain, both of which may increase the risk of cardiovascular disease [6,18].”
BackgroundLo, S., Yang, Y., Kornelius, E., Huang, J., Lai, Y., Huang, C., & Chiou, J. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13746 · Cited by 14
“5 years.(16) The Atherosclerosis Risk in Communities (ARIC) study, a prospective cohort analysis, showed that the risk of cardiovascular outcomes and mortality was highest during the first year after severe hypoglycaemia.”
BackgroundEscalada, J., Liao, L., Pan, C., Wang, H., & BALA, M. M. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1189893 · Cited by 15
The Role of Platelets in Hypoglycemia-Induced Cardiovascular Disease: A Review of the Literature
Ali, A. A. G., Niinuma, S. A., Moin, A. S. M., Atkin, S. L., & Butler, A. E. (2023) · Biomolecules · doi:10.3390/biom13020241 · Cited by 14
“The risk of CVD events has been shown to persist months or years after the hypoglycemic episode [61].”
BackgroundVerhulst, C. E. M., van Heck, J. I. P., Fabricius, T. W., Stienstra, R., Teerenstra, S., McCrimmon, R. J., Tack, C. J., Pedersen‐Bjergaard, U., & de Galan, B. E. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15205 · Cited by 14
Transporter Proteins as Therapeutic Drug Targets—With a Focus on SGLT2 Inhibitors
Komaniecka, N., Maroszek, S., Droździk, M., Oswald, S., & Droździk, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136926 · Cited by 15
“Developing a drug to lower glucose levels involves the risk of hypoglycemia, which can impair cardioprotective effects due to the activation of the sympathetic nervous sys-tem [58].”
BackgroundMita, T., Katakami, N., Shiraiwa, T., Yoshii, H., Kuribayashi, N., Osonoi, T., Kaneto, H., Kosugi, K., Umayahara, Y., Gosho, M., et al. (2017) · Scientific Reports · doi:10.1038/srep39965 · Cited by 15
Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS
Vallon, V., & Thomson, S. C. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.113 · Cited by 15
Liu, Y., Li, W., Chen, Y., & Wang, X. (2023) · Endocrine · doi:10.1007/s12020-023-03499-0 · Cited by 14
“The patients with T1D are associated with an almost threefold increase in all-cause mortality than the general population [4].”
Hypoglycemia and Cardiovascular Disease: Lessons from Outcome Studies
Pistrosch, F., & Hanefeld, M. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0678-2 · Cited by 14
Miller, R. G., & Costacou, T. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1240-4 · Cited by 16
Deceased organ donor factors influencing pancreatic graft transplantation and survival
Sally, M. B., Ellis, M. K. M., Hutchens, M. P., Groat, T., Swanson, E. A., Patel, M. S., Niemann, C. U., & Malinoski, D. (2019) · Clinical Transplantation · doi:10.1111/ctr.13571 · Cited by 12
Hu, X., Xu, W., Lin, S., Zhang, C., Ling, C., & Chen, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/7292108 · Cited by 14
“Severe hypoglycemia can cause damage to multiple organ functions resulting in cardiovascular and cerebrovascular diseases, loss of consciousness, and even death [10].”
BackgroundVig, H., Ravinandan, A. P., Vishwas, H. N., Tyagi, S., Rathore, S., Wal, A., & Wal, P. (2023) · Current Diabetes Reviews · doi:10.2174/1573399819666230502110511 · Cited by 14
Hypoglycaemia Among Diabetes Patients: A Preventive Approach
Mohajan, D., & Mohajan, H. K. (2023) · Journal of Innovations in Medical Research · doi:10.56397/jimr/2023.09.05 · Cited by 17
Pedersen, C., Bouman, S. D., Porsgaard, T., ROSENKILDE, M. M., & Roed, N. K. (2018) · Physiological Reports · doi:10.14814/phy2.13657 · Cited by 12
“Furthermore, hypoglycemia has been associated with increased risk of cardiovascular events and mortality (Ismail-Beigi et al. 2010; Khunti et al. 2015).”
BackgroundSenior, P. A. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.09.001 · Cited by 12
Henao-Carrillo, D. C., Sierra-Matamoros, F. A., Carrillo Algarra, A. J., García-Lugo, J. P., & Hernández-Zambrano, S. M. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102917 · Cited by 11
Nakajima, K., Mita, T., Osonoi, Y., Azuma, K., Takasu, T., Fujitani, Y., & Watada, H. (2015) · International Journal of Endocrinology · doi:10.1155/2015/406394 · Cited by 12
BRUGINSKI, D., Précoma, D. B., Sabbag, A. E., & Olandowski, M. (2019) · Current Diabetes Reviews · doi:10.2174/1573399815999190619141622 · Cited by 13
Jaffa, M. A., Bebu, I., Luttrell, D. K., Braffett, B. H., Lachin, J. M., Hunt, K. J., Lopes-Virella, M. F., Luttrell, L. M., Lyons, T. J., & Jaffa, A. A. (2020) · Diabetes · doi:10.2337/db20-0427 · Cited by 11
Myers, L. A., Swanson, K. M., Glasgow, A. E., & McCoy, R. G. (2022) · Diabetes Care · doi:10.2337/dc21-1811 · Cited by 16
Huang, C., Wang, W., Sung, S., Chen, C., Lip, G. Y. H., Cheng, H., & Chiang, C. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14819 · Cited by 13
Kugathasan, L., Sridhar, V. S., Tommerdahl, K. L., Xu, C., Bjornstad, P., Advani, A., & Cherney, D. Z. I. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155785 · Cited by 11
Rauh, S. P., Rutters, F., Thorsted, B. L., Wolden, M. L., Nijpels, G., van der Heijden, A. A. W. A., Walraven, I., Elders, P. J. M., Heymans, M. W., & Dekker, J. M. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012793 · Cited by 14
Self-citationon behalf of the Hypoglycemia as a Quality Measure in Diabetes Study Group, Rodríguez‐Gutiérrez, R., Salcido‐Montenegro, A., Ospina, N. S., Maraka, S., Iñiguez‐Ariza, N. M., Spencer‐Bonilla, G., Tamhane, S. U., Lipska, K. J., Montori, V. M., et al. (2019) · Endocrine · doi:10.1007/s12020-019-02147-w · Cited by 11
All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine
Strandberg, A. Y., Hoti, F. J., Strandberg, T. E., Christopher, S., Haukka, J. K., & Korhonen, P. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151910 · Cited by 13
Proximal HbA1C Level and First Hypoglycemia Hospitalization in Adults With Incident Type 2 Diabetes
Zhong, V. W., Juhaeri, J., Cole, S. R., Shay, C. M., Gordon‐Larsen, P., Kontopantelis, E., & Mayer‐Davis, E. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01402 · Cited by 9
Hypoglycemia during hyperosmolar hyperglycemic crises is associated with long-term mortality
González‐Vidal, T., Lambert, C., García, A. V., Villa-Fernández, E., Pujante, P., Ares, J., Torre, E. L. M., & Delgado, E. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01329-5 · Cited by 12
Asl, Z. R., Rezaee, K., Ansari, M., Zare, F., & Roknabadi, M. H. A. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.135988 · Cited by 15
Nardone, M., Kugathasan, L., Sridhar, V. S., Dutta, P., Campbell, D. J. T., Layton, A. T., Perkins, B. A., Barbour, S. J., Lam, T. K. T., Levin, A., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000641 · Cited by 11
“People with type 1 diabetes (T1D) have elevated risks of cardiovascular disease (CVD) and kidney failure compared with the general population, 1,2 even with intensive glycemic and BP management, renin-angiotensin system inhibition and statins.”
Yang, Y., Liu, Z., Lin, B., HUANG, Y. ‐., Deng, H., Yang, X., Zeng, L., Yan, J., & Xu, W. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01732-6 · Cited by 13
“Hepatic lipid accumulation disrupts insulin’s suppression of gluconeogenesis, as evidenced by the association between microbiome-tar-geted therapies and reduced liver fat content [49].”
Saito, K., Okada, Y., Torimoto, K., Takamatsu, Y., & Tanaka, Y. (2021) · Sleep And Breathing · doi:10.1007/s11325-021-02442-9 · Cited by 11
Optimizing management of glycaemia
Chatterjee, S., Khunti, K., & Davies, M. J. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.002 · Cited by 15
Self-citationSGLT inhibitors for people with type 1 diabetes
Llano, A., McKay, G., & Fisher, M. (2019) · Practical Diabetes · doi:10.1002/pdi.2222 · Cited by 10
Charamba, B., Liew, A., Coen, E., Newell, J., O’Brien, T., Wijns, W. C., & Simpkin, A. J. (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.263 · Cited by 10
Cardiovascular safety of insulin: Between real‐world data and reality
Mannucci, E., & Ferrannini, E. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12967 · Cited by 9
Eeg‐Olofsson, K., Nathanson, D., Spelman, T. D., Kyhlstedt, M., Seibold, A., Levrat‐Guillen, F., & Bolinder, J. (2025) · Diabetologia · doi:10.1007/s00125-025-06438-y · Cited by 12
“However, prior severe hypoglycaemia events (SHEs) are reported to increase the risk of adverse CVD complications in people with type 1 diabetes [4], and SHEs are independently associated with accelerated atherosclerosis, increased risk of CVD events and all-cause mortality [5–7].”
Ri, M., Nunobe, S., Ida, S., Ishizuka, N., Atsumi, S., Hayami, M., Makuuchi, R., Kumagai, K., Ohashi, M., & Sano, T. (2021) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2021.21.e31 · Cited by 10
“Given that hypoglycemia is known to be associated with an increased risk of cardiovascular events and mortality [30-32], postprandial hypoglycemia might have a greater effect on the cardiovascular systems of post-TG-RY patients than in those who had undergone other forms of gastrectomy.”
Background
Metadata
- Authors
- Khunti, K., Davies, M., Majeed, A., Thorsted, B. L., Wolden, M. L., & Paul, S. K.
- Affiliations
- University of Leicester (GB)
- Imperial College London (GB)
- Novo Nordisk (Denmark) (DK)
- QIMR Berghofer Medical Research Institute (AU)
- Corresponding author
- Khunti, Kamlesh
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-12-09
- Volume
- 38
- Issue
- 2
- Pages
- 316-322
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2128592897
- Cited by
- 356
- References
- 32
- Citations by year
- 2026: 13 · 2025: 23 · 2024: 26 · 2023: 34 · 2022: 26 · 2021: 39 · 2020: 33 · 2019: 38 · 2018: 27 · 2017: 38 · 2016: 39 · 2015: 20
- FWCI
- 25.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- hypoglycemia, cardiovascular disease, all-cause mortality, type 1 diabetes, type 2 diabetes, insulin-treated diabetes, cardiovascular events, mortality risk
- MeSH terms
- Adult, Aged, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Angiopathies, England, Epidemiologic Methods, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Insulins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.